Share
3,169 Posts.
lightbulb Created with Sketch. 249
clock Created with Sketch. 21/10/23
08:37
Share
Originally posted by mattyedw:
↑
All in all i think this quarterly outlines whats to come, confidence imho is strong that there are no issues re-running the production run
Expand
"Following this meeting, the Company has engaged with several global pharmaceutical and biotechnology companies who are interested in Patrys’ deoxymab technology for applications ranging from cancer therapies through to the cellular and nuclear delivery of therapeutic payloads. These discussion are ongoing. ""Merck, flush with Keytruda cash and eyeing the loss of exclusivity on its megablockbuster, has agreed to pay $4 billion upfront to co-develop and co-commercialize three Daiichi ADCs. The numbers past that point rise to eye-watering levels. Merck has committed to $1.5 billion in continuation payments over the next 24 months and up to $16.5 billion in sales milestones. Merck pays $4B for Daiichi ADCs in bet on post-Keytruda future (fiercebiotech.com)
(20min delay)